Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium
Updated Results from Phase 2 Clinical Trial of KRX-0401 in Combination with Capecitabine for the treatment of Metastatic Colon Cancer to be Presented on Sunday, January 24, 2010
NEW YORK, Jan 21 /PRNewswire-FirstCall/ -- Keryx
Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that updated
results from its Phase 2 clinical trial of KRX-0401 (perifosine) in
combination with capecitabine has been selected for poster
presentation at the upcoming ASCO 2010 Gastrointestinal Cancers
Symposium, to be held in Orlando, Florida from January 22-24,
2010.
The clinical data to be presented demonstrates the potential
safety and efficacy of KRX-0401 in the treatment of patients with
metastatic colon cancer.
Details on the poster presentation are as follows:
Abstract #: 447
TITLE: A Randomized phase II study of perifosine in combination
with capecitabine (P-CAP) versus capecitabine plus placebo
(CAP) in patients with second- or third-line metastatic
colon cancer (mCRC): Updated results
Lead Author: Johanna Bendell, MD
Session Name: General Poster Session C:
Cancers of the Colon and Rectum
Date: Sunday, January 24, 2010
Presentation
Time: 7:00 AM - 8:00 AM; 12:00 NOON - 1:00 PM
A copy of the above referenced abstract can be viewed online
through the American Society of Clinical Oncology's website,
www.asco.org.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna
Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada
and Mexico.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of medically important
pharmaceutical products for the treatment of life-threatening
diseases, including cancer and renal disease. Keryx is developing
KRX-0401 (perifosine), a novel, potentially first-in-class, oral
anti-cancer agent that inhibits the phosphoinositide 3-kinase
(PI3K)/Akt pathway, a key signaling cascade that has been shown to
induce cell growth and cell transformation. KRX-0401 has
demonstrated both safety and clinical efficacy in several tumor
types, both as a single agent and in combination with novel
therapies. KRX-0401 also modulates a number of other key signal
transduction pathways, including the JNK pathway, which are
pathways associated with programmed cell death, cell growth, cell
differentiation and cell survival. KRX-0401 is currently in a Phase
3 trial, under Special Protocol Assessment (SPA), in multiple
myeloma, and in Phase 2 clinical development for several other
tumor types. Keryx is also developing Zerenex(TM) (ferric citrate),
an oral, iron-based compound that has the capacity to bind to
phosphate and form non-absorbable complexes. The Phase 3 clinical
program of Zerenex in the treatment for hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease is
expected to begin this quarter under an SPA agreement with the FDA.
Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release,
particularly those anticipating future clinical and business
prospects for KRX-0401 (perifosine), may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: our
ability to successfully complete clinical trials for KRX-0401; our
ability to meet anticipated development timelines for KRX-0401 due
to recruitment, clinical trial results, manufacturing capabilities
or other factors; and other risk factors identified from time to
time in our reports filed with the Securities and Exchange
Commission. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not
intend to update any of these forward-looking statements to reflect
events or circumstances that occur after the date hereof. This
press release and prior releases are available at http://www.keryx.com/. The information in our
website and in the American Society of Clinical Oncology's website
is not incorporated by reference into this press release and is
included as an inactive textual reference only.
KERYX CONTACT: Lauren Fischer Director, Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5962 E-mail: lfischer@keryx.com
Source: Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director, Investor Relations,
Keryx
Biopharmaceuticals, Inc., +1-212-531-5962, lfischer@keryx.com
Web Site: http://www.keryx.com/
Posted: January 2010
